Literature DB >> 23777310

Incidence of second primary malignancies in patients with esophageal cancer: a comprehensive review.

Nina Nandy1, Constantin A Dasanu.   

Abstract

BACKGROUND: Development of a second primary malignancy (SPM) after an index esophageal cancer is fairly rare, primarily due to decreased survival in patients with esophageal cancer. However, with advances in early detection and therapy, the number of long-term survivors is increasing, as is the incidence of SPMs in this population. SCOPE: We review herein the published literature on the incidence of SPMs after an index esophageal cancer as well as its associated risk factors, prognosis and surveillance. We discuss predisposing factors that may contribute to the development of SPMs, epidemiology and attempts at chemoprevention.
FINDINGS: Data from population-based studies, retrospective reviews and case reports indicate an increased risk of SPMs in patients with esophageal cancer with reported incidence rates between 8.3 and 27.1%. Index esophageal squamous cell carcinomas have a higher association with other tobacco-related cancers such as those of the head and neck and lung. They have also shown an association with second primary cancers of the breast, stomach, thyroid, and kidney. Individuals with esophageal adenocarcinomas are at a higher risk of developing second cancers of the stomach, oropharynx and lung/bronchus. Other primary cancer sites involved include the kidney, colorectum and pancreas. Common risk factors including lifestyle and genetic alterations may explain the increased incidence of second primary cancers in this patient population.
CONCLUSIONS: Risk of developing a second malignancy should be anticipated after curative treatment of esophageal cancer, and raises concerns for optimal surveillance and therapy of these patients. Recent literature suggests similar survival rates in esophageal cancer patients with and without SPMs. With the increasing incidence of SPMs in subjects with esophageal cancer, there may be benefit to close screening for and aggressive therapy of SPMs. However, further studies are needed to elucidate optimal management strategies.

Entities:  

Mesh:

Year:  2013        PMID: 23777310     DOI: 10.1185/03007995.2013.816276

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  15 in total

1.  Effect of prior cancer on outcomes in advanced lung cancer: implications for clinical trial eligibility and accrual.

Authors:  Andrew L Laccetti; Sandi L Pruitt; Lei Xuan; Ethan A Halm; David E Gerber
Journal:  J Natl Cancer Inst       Date:  2015-02-09       Impact factor: 13.506

2.  Type of second primary malignancy after achieving complete response by definitive chemoradiation therapy in patients with esophageal squamous cell carcinoma.

Authors:  Toshifumi Yamaguchi; Ken Kato; Kengo Nagashima; Satoru Iwasa; Yoshitaka Honma; Atsuo Takashima; Tetsuya Hamaguchi; Yoshinori Ito; Jun Itami; Narikazu Boku; Kazuhide Higuchi
Journal:  Int J Clin Oncol       Date:  2018-03-08       Impact factor: 3.402

3.  Development and validation of a competing risk model for second primary pancreatic ductal adenocarcinoma: A population-based study.

Authors:  Lishan Song; Chaojie Xu; Tong Zhang; Shengyang Chen; Zhigang Shi; Shuiquan Hu; Bingbing Cheng; Hao Tong; Guangkun Wei; Xiaoyong Li
Journal:  Front Surg       Date:  2022-08-30

4.  Better Prognosis and Survival in Esophageal Cancer Survivors After Comorbid Second Primary Malignancies: A SEER Database-Based Study.

Authors:  Jiayue Ye; Sheng Hu; Wenxiong Zhang; Deyuan Zhang; Yang Zhang; Dongliang Yu; Jinhua Peng; Jianjun Xu; Yiping Wei
Journal:  Front Surg       Date:  2022-05-06

5.  Incidence and risk factors of synchronous colorectal cancer in patients with esophageal cancer: an analysis of 480 consecutive colonoscopies before surgery.

Authors:  Naoya Yoshida; Yuka Tamaoki; Yoshifumi Baba; Yasuo Sakamoto; Yuji Miyamoto; Masaaki Iwatsuki; Takashi Shono; Hideaki Miyamoto; Masanori Imuta; Junji Kurashige; Hiroshi Sawayama; Ryuma Tokunaga; Masayuki Watanabe; Yutaka Sasaki; Yasuyuki Yamashita; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2016-07-01       Impact factor: 3.402

6.  Esophageal Squamous Cell Carcinoma Patients Have an Increased Risk of Coexisting Colorectal Neoplasms.

Authors:  Myong Ki Baeg; Myung-Gyu Choi; Yun Duk Jung; Sun-Hye Ko; Chul-Hyun Lim; Hyung Hun Kim; Jin Su Kim; Yu Kyung Cho; Jae Myung Park; In Seok Lee; Sang-Woo Kim
Journal:  Gut Liver       Date:  2016-01       Impact factor: 4.519

7.  Do Esophageal Squamous Cell Carcinoma Patients Have an Increased Risk of Coexisting Colorectal Neoplasms?

Authors:  Byung Ik Jang; Moon Joo Hwang
Journal:  Gut Liver       Date:  2016-01       Impact factor: 4.519

8.  Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle.

Authors:  Dionysios Dellaportas; James A Gossage; Andrew R Davies
Journal:  Case Rep Surg       Date:  2016-08-18

9.  Non-participation in breast cancer screening for women with chronic diseases and multimorbidity: a population-based cohort study.

Authors:  L F Jensen; A F Pedersen; B Andersen; M Vestergaard; P Vedsted
Journal:  BMC Cancer       Date:  2015-10-26       Impact factor: 4.430

10.  Importance of colonoscopy in patients undergoing endoscopic resection for superficial esophageal squamous cell carcinoma.

Authors:  Kei Tominaga; Hisashi Doyama; Hiroyoshi Nakanishi; Naohiro Yoshida; Yasuhito Takeda; Ryosuke Ota; Kunihiro Tsuji; Kazuhiro Matsunaga; Shigetsugu Tsuji; Kenichi Takemura; Shinya Yamada; Kazuyoshi Katayanagi; Hiroshi Kurumaya
Journal:  Ann Gastroenterol       Date:  2016-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.